Company Overview - The company, Boai New Kaineng Medical Technology Group Co., Ltd., specializes in fine chemicals and precision medicine, with key products including PVPK30, PVP-I, PVP series, and early cancer diagnosis services [1] - The latest financial report indicates that for Q1 2025, the company achieved a revenue of 325 million yuan, a year-on-year decrease of 17.69%, and a net profit of 80.42 million yuan, down 33.75%, with a gross profit margin of 44.07% [1] Market Performance - As of June 9, the company's stock closed at 17.83 yuan, reflecting an increase of 2.77%, with a rolling price-to-earnings (PE) ratio of 27.99, marking a new low in 48 days [1] - The total market capitalization of the company is 8.642 billion yuan [1] - In terms of capital flow, on June 9, the company saw a net inflow of 3.2614 million yuan, with a total inflow of 10.0675 million yuan over the past five days [1] Industry Comparison - The average PE ratio for the chemical products industry is 43.87, with a median of 39.46, positioning the company at 81st in the industry ranking [2] - The company's static PE is 24.71, and its price-to-book ratio is 2.33 [2]
新开源收盘上涨2.77%,滚动市盈率27.99倍,总市值86.42亿元